KRT1 and urinary bladder neoplasm: In the present study, we employed Ad5WS1 in combination with Ad/K1–5, an E1-deleted, replication-defective adenoviral vector expressing angiogenic inhibitors, for the treatment of TCC-SUP bladder tumour xenografts.